Lupin Ltd. Therapeutic and Drug Pipeline Review



Global Lupin Ltd. Drugs and Companies Pipeline Review 2017

PUNE, INDIA, February 28, 2017 / -- The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Get Sample Report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited
- The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lupin Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lupin Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
- Evaluate Lupin Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupin Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupin Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 5
Lupin Limited Snapshot 6
Lupin Limited Overview 6
Key Information 6
Key Facts 6
Lupin Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Lupin Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Lupin Limited - Pipeline Products Glance 12
Lupin Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lupin Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Lupin Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Lupin Limited - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Lupin Limited - Drug Profiles 18
Biosimilar for Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
etanercept biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LND-101001 20
Product Description 20

Access Report @

Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.